Free Trial
NASDAQ:ANIX

Anixa Biosciences Q2 2025 Earnings Report

Anixa Biosciences logo
$3.01 +0.06 (+2.03%)
Closing price 04:00 PM Eastern
Extended Trading
$3.00 -0.01 (-0.33%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 28, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Anixa Biosciences' Q3 2025 earnings is scheduled for Friday, September 5, 2025, with a conference call scheduled on Wednesday, September 3, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Anixa Biosciences Earnings Headlines

When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat